CIRCULOGENE Announces Appointment of Bob Gasparini to Board of Directors
BIRMINGHAM, Ala. and PENSACOLA, Fla., Dec. 8, 2022 /PRNewswire-PRWeb/ -- CIRCULOGENE is an innovative liquid biopsy company transforming precision medicine through the rapid and cost-effective delivery of actionable results and the only laboratory in the world that reports levels of the immunotherapy biomarker PD-L1 with a simple blood test. CIRCULOGENE is proud to announce the appointment of Robert "Bob" Gasparini, M.H.S., M.S., CG(ASCP), DLM(ASCP), to its Board of Directors. Prior to his retirement in 2021, Mr. Gasparini was a medical laboratory executive for over 20 years with proven success building multi-site laboratory infrastructure, troubleshooting technical issues across multiple testing platforms, and developing corporate-wide staff and client training programs. His specialized cancer testing expertise includes a focus in Cytogenetics and Fluorescence In-situ Hybridization (FISH).